McKesson buying Irish wholesaler; BMS announces dividend;

@FiercePharma: India's Sun Pharma makes $48M purchase of eyecare firm InSite Vision. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. FiercePharmaManufacturing item | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo officially rejects Mylan's 'insulting,' 'ego'-driven buyout offer. Item | Follow @CarlyHFierce

> Bristol-Myers Squibb ($BMY) has declared a quarterly dividend of 37 cents per share payable November 2 to stockholders of record at the close of business on October 2. Report

> Drug wholesaler McKesson ($MCK) has a deal to buy the pharmaceutical distribution division of UDG Healthcare, based in Northern Ireland and the Republic of Ireland, for €408 million in cash. Release

> Swiss health authorities have approved Novartis' ($NVS) Entresto. Release

> Mylan ($MYL) has launched a generic version of Novartis cholesterol med Lescol XL. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: U.K. scientists develop ultrasonic device to better clean medical instruments. Article | Follow @FierceMedDev

@EmilyWFierce: Jaychem Industries is feeling the burn from an FDA warning letter over its GolfersSkin Sunscreen. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Penumbra goes public in upsized $120M deal, med tech's largest IPO of 2015. Story

> Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article

> FDA cautions against improperly cleaned bronchoscope devices. More

Biotech News

@FierceBiotech: RegenX IPO raises $138M, renewing hopes for a big Q4 biotech run. Article | Follow @FierceBiotech

@JohnCFierce: Allergan and Richter win FDA approval for a once-rejected schizophrenia pill. News | Follow @JohnCFierce

> NIH pushes forward in Obama's $215M 'precision medicine' plan. News

> Nabriva pulls off a down-sized IPO, raising $92M for antibiotic R&D. Story

> FierceBiotech Radio on 'amazing' diabetes data, biotech's VC boom, and Severin Schwan's hot mic. More

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.